Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Evonik targets EV battery recycling, food tech in innovation drive

Published 09/15/2022, 10:20 AM
Updated 09/15/2022, 10:27 AM
© Reuters. FILE PHOTO: The logo of German specialty chemical company Evonik Industries AG is pictured at their plant in Bitterfeld, Germany, February 29, 2016. REUTERS/Fabrizio Bensch

GDANSK (Reuters) - Germany's Evonik Industries is working on ways to help recycle lithium from electric car batteries and limit the need for crop fertilisers as part of an innovation drive already tipped to add 1 billion euros ($998 million) to sales in the 10 years to 2025.

At its innovation conference on Thursday, the speciality chemicals company said it saw electric vehicles, food production and meat testing as three particularly interesting fields.

According to Evonik, up to 95% of the lithium in lithium-ion electric vehicle batteries is not being recycled, mainly due to high costs.

Its solution, currently being tested on a pilot scale, increases efficiency using an electrochemical process with a ceramic membrane, which results in battery-grade lithium for use in new cells.

Evonik's specialists are confident the ceramic membrane process will be market ready in three to five years, it said.

For agriculture, the company is developing bacteria as biostimulants to supply nitrogen needed to grow cereals such as wheat and corn, instead of energy-intensive synthetic fertilisers.

"Our idea was to provide the plants with nitrogen from the atmosphere with bacteria. If this idea is successful this makes a major contribution to sustainability...," said Jan Wolter who heads the farm-to-fork division at Evonik's innovation unit Creavis.

The company said it expected to launch the first biostimulant formulations commercially between 2025 and 2027.

It is also working on technology to help determine the origin and quality of chicken products, aiming to tap into consumer demand for increased transparency.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Development work on the product, which uses an epigenetics and bioinformatics platform to test for a multitude of animal welfare factors, is well advanced and specific tests can be made available to customers in the short- to mid-term, Evonik said.

($1 = 1.0017 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.